Biotech sector performance accelerated in 2025, fueled by M&A and clinical updates, with portfolio outperformance from key holdings. Productivity gains from a new operating system and AI transformation support a broad investment approach amid challenging valuations.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.